Gravidez molar

Horowitz NS, Eskander RN, Adelman MR, et al. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. Gynecol Oncol. 2021 Dec;163(3):605-13.Texto completo  Resumo

Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):86-93.Texto completo  Resumo

Tidy, J, Seckl, M, Hancock, BW, on behalf of the Royal College of Obstetricians and Gynaecologists. Management of gestational trophoblastic disease. BJOG 2021;128: e1-e27​.Texto completo

Lok C, van Trommel N, Massuger L, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020 May;130:228-40. Resumo

1. Hancock BW. Staging and classification of gestational trophoblastic disease. Clin Obstet Gynecol Best Pract Res. 2003 Dec;17(6):869-83. Resumo

2. Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. J Obstet Gynaecol Can. 2021 Jan;43(1):91-105.e1.Texto completo  Resumo

3. Horowitz NS, Eskander RN, Adelman MR, et al. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. Gynecol Oncol. 2021 Dec;163(3):605-13.Texto completo  Resumo

4. Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):86-93.Texto completo  Resumo

5. Altieri A, Franceschi S, Ferlay J, et al. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003 Nov;4(11):670-8. Resumo

6. Kim SJ, Bae SN, Kim JH, et al. Epidemiology and time trends of gestational trophoblastic disease in Korea. Int J Gynaecol Obstet. 1998 Apr;60 Suppl 1:S33-8. Resumo

7. Braga A, Uberti EM, Fajardo Mdo C, et al. Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers: results after 12 years since International FIGO 2000 Consensus. J Reprod Med. 2014 May-Jun;59(5-6):241-7. Resumo

8. Sebire NJ, Fisher RA, Foskett M, et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG. 2003 Jan;110(1):22-6. Resumo

9. Vargas R, Barroilhet LM, Esselen K, et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med. 2014 May-Jun;59(5-6):188-94. Resumo

10. Altman AD, Bentley B, Murray S, et al. Maternal age-related rates of gestational trophoblastic disease. Obstet Gynecol. 2008 Aug;112(2 Pt 1):244-50. Resumo

11. Savage PM, Sita-Lumsden A, Dickson S, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 2013 May;33(4):406-11.Texto completo  Resumo

12. Gockley AA, Melamed A, Joseph NT, et al. The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. Gynecol Oncol. 2016 Mar;140(3):470-3. Resumo

13. Di Cintio E, Parazzini F, Rosa C, et al. The epidemiology of gestational trophoblastic disease. Gen Diagn Pathol. 1997 Nov;143(2-3):103-8. Resumo

14. Braga A, Growdon WB, Bernstein M, et al. Molar pregnancy in adolescents. J Reprod Med. 2012 May-Jun;57(5-6):225-30. Resumo

15. Soares RR, Maestá I, Colón J, et al. Complete molar pregnancy in adolescents from North and South America: Clinical presentation and risk of gestational trophoblastic neoplasia. Gynecol Oncol. 2016 Sep;142(3):496-500. Resumo

16. Zheng XZ, Qin XY, Chen SW, et al. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. Mod Pathol. 2020 Oct;33(10):1979-88.Texto completo  Resumo

17. Demond H, Anvar Z, Jahromi BN, et al. A KHDC3L mutation resulting in recurrent hydatidiform mole causes genome-wide DNA methylation loss in oocytes and persistent imprinting defects post-fertilisation. Genome Med. 2019 Dec 17;11(1):84.Texto completo  Resumo

18. Sanchez-Delgado M, Martin-Trujillo A, Tayama C, et al. Absence of maternal methylation in biparental hydatidiform moles from women with NLRP7 maternal-effect mutations reveals widespread placenta-specific imprinting. PLoS Genet. 2015 Nov;11(11):e1005644.Texto completo  Resumo

19. Lin LH, Maestá I, St Laurent JD, et al. Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. Am J Obstet Gynecol. 2021 Apr;224(4):372.e1-372.e30. Resumo

20. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol. 1978 Jul 15;131(6):665-71. Resumo

21. Szulman AE, Surti U. The syndromes of hydatidiform mole. II. Morphologic evaluation of the complete and partial mole. Am J Obstet Gynecol. 1978 Sep 1;132(1):20-7. Resumo

22. Soper JT. Gestational trophoblastic disease. Obstet Gynecol. 2006 Jul;108(1):176-87. Resumo

23. Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med. 1996 Dec 5;335(23):1740-8. Resumo

24. Braga A, Moraes V, Maestá I, et al. Changing trends in the clinical presentation and management of complete hydatidiform mole among Brazilian women. Int J Gynecol Cancer. 2016 Jun;26(5):984-90. Resumo

25. Sun SY, Melamed A, Goldstein DP, et al. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol. 2015 Jul;138(1):46-9. Resumo

26. Ramos MM, Maesta I, de Araújo Costa RA, et al. Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism. Gynecol Oncol. 2022 Apr;165(1):137-42. Resumo

27. Berkowitz RS, Cramer DW, Bernstein MR, et al. Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol. 1985 Aug 15;152(8):1016-20. Resumo

28. Parazzini F, La Vecchia C, Mangili G, et al. Dietary factors and risk of trophoblastic disease. Am J Obstet Gynecol. 1988 Jan;158(1):93-9. Resumo

29. Ferraz L, Ramos CAB, Braga A, et al. Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. Clinics (Sao Paulo). 2020;75:e1724.Texto completo  Resumo

30. Lok C, Frijstein M, van Trommel N. Clinical presentation and diagnosis of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:42-52.Texto completo  Resumo

31. American College of Obstetricians and Gynecologists​. ACOG practice bulletin no. 175: ultrasound in pregnancy. Dec 2016 [internet publication].Texto completo

32. Tranoulis A, Georgiou D, Sayasneh A, et al. Gestational trophoblastic neoplasia: a meta-analysis evaluating reproductive and obstetrical outcomes after administration of chemotherapy. Int J Gynecol Cancer. 2019 Jul;29(6):1021-31. Resumo

33. Beguin Y, Huebers HA, Josephson B, et al. Transferrin receptors in rat plasma. Proc Natl Acad Sci U S A. 1988 Jan;85(2):637-40.Texto completo  Resumo

34. Tidy, J, Seckl, M, Hancock, BW, on behalf of the Royal College of Obstetricians and Gynaecologists. Management of gestational trophoblastic disease. BJOG 2021;128: e1-e27​.Texto completo

35. Soto-Wright V, Bernstein M, Goldstein DP, et al. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol. 1995 Nov;86(5):775-9. Resumo

36. Sun SY, Melamed A, Joseph NT, et al. Clinical presentation of complete hydatidiform mole and partial hydatidiform mole at a regional trophoblastic disease center in the United States over the past 2 decades. Int J Gynecol Cancer. 2016 Feb;26(2):367-70. Resumo

37. Lurain JR. Hydatidiform mole: recognition and management​. Contemporary OB/GYN. 2019;64(3).​Texto completo

38. Yamazaki K, Sato K, Shizume K, et al. Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles. J Clin Endocrinol Metab. 1995 Feb;80(2):473-9. Resumo

39. Bhatia N, Mitharwal SM. Hydatidiform mole with uncontrolled hyperthyroidism: an anesthetic challenge. J Anaesthesiol Clin Pharmacol. 2016 Oct-Dec;32(4):537-8.Texto completo  Resumo

40. Norman RJ, Green-Thompson RW, Jialal I, et al. Hyperthyroidism in gestational trophoblastic neoplasia. Clin Endocrinol (Oxf). 1981 Oct;15(4):395-401. Resumo

41. Coyle C, Short D, Jackson L, et al. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients. Gynecol Oncol. 2018 Feb;148(2):254-7. Resumo

42. Lok C, van Trommel N, Massuger L, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020 May;130:228-40. Resumo

43. American College of Radiology. ACR-ACOG-AIUM-SRU practice parameter for the performance of obstetrical ultrasound. 2018 [internet publication].Texto completo

44. Berkowitz RS, Tuncer ZS, Bernstein MR, et al. Management of gestational trophoblastic diseases: subsequent pregnancy experience. Semin Oncol. 2000 Dec;27(6):678-85. Resumo

45. Lorigan PC, Sharma S, Bright N, et al. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol. 2000 Sep;78(3 Pt 1):288-92. Resumo

46. Sand PK, Lurain JR, Brewer JI. Repeat gestational trophoblastic disease. Obstet Gynecol. 1984 Feb;63(2):140-4. Resumo

47. Matthews A, Haas DM, O'Mathúna DP, Dowswell T. Interventions for nausea and vomiting in early pregnancy. Cochrane Database of Syst Rev. 2015 Sep 08;(9):CD007575. Texto completo

48. Coukos G, Makrigiannakis A, Chung J, et al. Complete hydatidiform mole. A disease with a changing profile. J Reprod Med. 1999 Aug;44(8):698-704. Resumo

49. American College of Radiology. ​ACR appropriateness criteria®: first trimester vaginal bleeding. 2017 [internet publication].Texto completo

50. Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. 2021 Feb 1;137(2):355-70.Texto completo  Resumo

51. Pereira JV, Lim T. Hyperthyroidism in gestational trophoblastic disease - a literature review. Thyroid Res. 2021 Jan 14;14(1):1.Texto completo  Resumo

52. American College of Obstetricians and Gynecologists. ​Practice bulletin no. 181: prevention of Rh D alloimmunization. Aug 2017 [internet publication].Texto completo

53. Padrón L, Rezende Filho J, Amim Junior J, et al. Manual compared with electric vacuum aspiration for treatment of molar pregnancy. Obstet Gynecol. 2018 Apr;131(4):652-9. Resumo

54. Faculty of Sexual & Reproductive Healthcare. FSRH GL on contraception after pregnancy​. Jan 2017 [internet publication].Texto completo

55. Braga A, Maestá I, Short D, et al. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review. BJOG. 2016 Jul;123(8):1330-5.Texto completo  Resumo

56. Dantas PRS, Maestá I, Filho JR, et al. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? Gynecol Oncol. 2017 Nov;147(2):364-370. Resumo

57. Zhao P, Lu Y, Huang W, et al. Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis. BMC Cancer. 2019 Jan 7;19(1):13.Texto completo  Resumo

58. Braga A, Lima L, Parente RCM, et al. Management of symptomatic uterine arteriovenous malformations after gestational trophoblastic disease: the Brazilian experience and possible role for depot medroxyprogesterone acetate and tranexamic acid treatment. J Reprod Med. 2018; 63: 228-39.Texto completo

59. American College of Obstetricians and Gynecologists​. ACOG practice bulletin no. 222: gestational hypertension and preeclampsia. Jun 2020 [internet publication].Texto completo

60. National Institute for Health and Care Excellence. ​Hypertension in pregnancy: diagnosis and management. 25 Jun 2019 [internet publication].Texto completo

61. Medicines and Healthcare products Regulatory Agency. Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy. May 2019 [internet publication].Texto completo

62. Food and Drug Administration. Drug Safety Communication: FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. May 2013 [internet publication].Texto completo

63. Lin LH, Maestá I, Braga A, et al. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: a retrospective multicenter cohort and literature review. Gynecol Oncol. 2017 Apr;145(1):88-95. Resumo

64. Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017 Sep 11;(9):CD007289.Texto completo  Resumo

65. European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. Jul 2013 [internet publication].Texto completo

66. UK Teratology Information Service. Official response statement: use of ondansetron in the first trimester of pregnancy. Sep 2019 [internet publication].Texto completo

67. Huybrechts KF, Hernández-Díaz S, Straub L, et al. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. JAMA. 2018 Dec 18;320(23):2429-37.Texto completo  Resumo

68. Medicines and Healthcare products Regulatory Agency. Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy. Jan 2020 [internet publication].Texto completo

69. Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018 Jul;13:291-310.Texto completo  Resumo

70. Bose S, Gothoskar BP, Coutinho WG, et al. Differential sensitivity of protein synthesis in human cell lines to actinomycin D. Exp Cell Res. 1967 Jun;46(3):599-603. Resumo

71. Horowitz NS, Goldstein DP, Berkowitz RS. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: biology, natural history, and treatment modalities. Gynecol Oncol. 2017 Jan;144(1):208-14. Resumo

72. Kaur B, Short D, Fisher RA, et al. Atypical placental site nodule (APSN) and association with malignant gestational trophoblastic disease; a clinicopathologic study of 21 cases. Int J Gynecol Pathol. 2015 Mar;34(2):152-8. Resumo

73. Gilman Barber AR, Rhone SA, Fluker MR. Curettage and Asherman's syndrome-lessons to (re-) learn? J Obstet Gynaecol Can. 2014 Nov;36(11):997-1001.Texto completo  Resumo

74. Lee SH, Aggarwal BB, Rinderknecht E, et al. The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin. J Immunol. 1984 Sep;133(3):1083-6. Resumo